Get the Stockscreener App
2.41
3.60%
-0.09
After Hours:
2.37
-0.04
-1.66%
Elevai Labs Inc stock is traded at $2.41, with a volume of 903.99K.
It is down -3.60% in the last 24 hours and down -88.10% over the past month.
See More
Previous Close:
$2.50
Open:
$2.34
24h Volume:
903.99K
Relative Volume:
1.44
Market Cap:
$994.93K
Revenue:
$1.44M
Net Income/Loss:
$-3.21M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-43.69%
1M Performance:
-88.10%
6M Performance:
-98.20%
1Y Performance:
-99.70%
1-Day Range:
$2.045
$2.60
1-Week Range:
$2.045
$4.20
52-Week Range:
$2.045
$840.00
Elevai Labs Inc Stock (ELAB) Company Profile
Name
Elevai Labs Inc
Sector
Industry
Phone
18667944940
Address
120 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare ELAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAB
Elevai Labs Inc
|
2.41 | 994.93K | 1.44M | -3.21M | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Elevai Labs Inc Stock (ELAB) Latest News
ELEVAI Labs Inc trading halted, news pending - TipRanks
Elevai Labs Inc. adjusts shareholder meeting quorum By Investing.com - Investing.com UK
Elevai Labs stock plunges to 52-week low of $0.02 By Investing.com - Investing.com South Africa
Elevai Labs stock plunges to 52-week low of $0.02 - Investing.com
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess - GlobeNewswire
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - GlobeNewswire
Elevai Labs Announces 1-for-200 Reverse Split to Maintain Nasdaq Listing | ELAB Stock News - StockTitan
Elevai Labs Withdraws Stock Exchange Offer Due to DTC Technical Issues | ELAB Stock News - StockTitan
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) - Simply Wall St
CORRECTIONElevai Labs Inc. - The Bakersfield Californian
Elevai Labs Reports Mixed Q3: 74.7% Margins, Revenue Dips 4.9% Amid $8M Offering | ELAB Stock News - StockTitan
Elevai Labs Inc (ELAB) Quarterly 10-Q Report - Quartzy
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update - GlobeNewswire
Elevai Labs granted extension to meet Nasdaq listing standards - Investing.com
Elevai Labs granted extension to meet Nasdaq listing standards By Investing.com - Investing.com Canada
Natural Gas (NGN23) Quote - The Globe and Mail
Carebook Technologies Inc (CRBKF) QuotePress Release - The Globe and Mail
Compugen (CGEN) Stock Surges Amidst Biotech Sector Volatility - GuruFocus.com
Elevai Labs announces update and extension of pending offer to exchange shares of common stock - MSN
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire
Elevai Labs strikes new executive agreements - Investing.com India
Elevai Labs strikes new executive agreements By Investing.com - Investing.com Nigeria
Columbia Sprtswr (COLM-Q) QuotePress Release - The Globe and Mail
Elevai Biosciences gears up for obesity drug IND submission By Investing.com - Investing.com Nigeria
Elevai Biosciences gears up for obesity drug IND submission - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., - GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - Yahoo Finance UK
Elevai reports promising preclinical obesity treatment results By Investing.com - Investing.com South Africa
Elevai reports promising preclinical obesity treatment results - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - The Manila Times
ELAB stock’s current quarter earnings estimates: What analysts predict? - US Post News
Elevai Labs Inc. Inc. (ELAB) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Metric Deep Dive: Understanding Elevai Labs Inc. (ELAB) Through its Ratios - The Dwinnex
Insider’s View: Deciphering Elevai Labs Inc. (ELAB)’s Financial Health Through Ratios - The Dwinnex
Views of Wall Street’s Leading Experts on Elevai Labs Inc. - SETE News
Elevai Labs Inc. [ELAB] is -94.09% lower this YTD. Is it still time to buy? - The DBT News
Elevai Labs Inc. (ELAB) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - The Manila Times
Elevai Labs Inc. Commences Offer to Exchange Up to - GlobeNewswire
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - The Manila Times
Elevai files patents for obesity treatment EL-22 By Investing.com - Investing.com Australia
Elevai files patents for obesity treatment EL-22 - Investing.com
This tiny skincare company is up big 💪 - RagingBull
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - StockTitan
Elevai Labs commences exosome skincare study By Investing.com - Investing.com South Africa
Elevai Labs commences exosome skincare study - Investing.com India
ELABElevai Labs, Inc. Latest Stock News & Market Updates - StockTitan
Elevai Labs Inc Stock (ELAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):